Skip to main content

Drug Interaction Report

2 potential interactions and/or warnings found for the following 2 drugs:

Filter by interaction and/or warning

Interactions between your drugs

Moderate

bismuth subcitrate potassium sarecycline

Applies to: De-Noltab (bismuth subcitrate potassium), sarecycline

ADJUST DOSING INTERVAL: Concomitant administration of bismuth-containing medications may impair the absorption of oral tetracyclines. The interaction has been studied with tetracycline and doxycycline. The proposed mechanism is chelation of tetracyclines by bismuth.

MANAGEMENT: Administration of a tetracycline and bismuth-containing preparation should either be avoided or separated by two to three hours. However, this precautionary measure is not considered necessary in treatment regimens where bismuth may be given in combination with tetracycline and other medications for the eradication of Helicobacter pylori infection, as the relative contribution of systemic versus local antimicrobial activity against Helicobacter pylori has not been established.

References (5)
  1. Ericsson CD, Feldman S, Pickering LK, Cleary TG (1982) "Influence of subsalicylate bismuth on absorption of doxycycline." JAMA, 247, p. 2266-7
  2. Albert KS, Welch RD, DeSante KA, DiSanto AR (1979) "Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture." J Pharm Sci, 68, p. 586-8
  3. (2018) "Product Information. Seysara (sarecycline)." Allergan Inc
  4. (2018) "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.
  5. (2025) "Product Information. Pylera (bismuth subcitrate potassium/metronidazo/TCN)." H2-Pharma LLC

Drug and food interactions

Moderate

bismuth subcitrate potassium food

Applies to: De-Noltab (bismuth subcitrate potassium)

ADJUST DOSING INTERVAL: Food may impair the gastrointestinal absorption and decrease the bioavailability of bismuth from the administration of bismuth subcitrate potassium (also known as colloidal bismuth subcitrate or tripotassium dicitratobismuthate). The clinical significance of this effect is unknown, as the relative importance of systemic versus local bismuth concentrations for antimicrobial activity against Helicobacter pylori has not been established. Investigators have suggested that the increased gastric retention time of bismuth in the presence of food may be beneficial by prolonging the local exposure of Helicobacter pylori to high concentrations of bismuth, although the amount of bismuth absorbed systemically and secreted back into the gastric fluid may also contribute to its therapeutic effect. When Pylera (a treatment preparation for Helicobacter pylori infection that contains bismuth subcitrate potassium 420 mg, metronidazole 375 mg, and tetracycline 375 mg per recommended dose) was administered after a standardized high-fat breakfast in 23 healthy volunteers, mean systemic exposure (AUC) for bismuth decreased by 60% compared to administration in the fasting state. Metronidazole and tetracycline AUC values were also reduced by 6% and 34%, respectively. However, these changes are not deemed clinically relevant, as eradication rates of Helicobacter pylori near 90% have been reported in trial patients administered Pylera routinely after meals.

MANAGEMENT: Pylera and generic equivalents should be administered after meals (breakfast, lunch, and dinner) and at bedtime (preferably with a snack). The manufacturers for some of the other bismuth subcitrate potassium products have recommended avoiding the ingestion of food, beverages, or other medications within one-half hour before and after each dose. The prescribing information or package labeling should be consulted for dosing and administration instructions that are appropriate for each product.

References (4)
  1. Cerner Multum, Inc (2015) "ANVISA Bulário Eletrônico."
  2. (2024) "Product Information. Pylera (bismuth subcitrate potassium/metronidazole/tetracycline)." Flynn Pharma Ltd
  3. (2025) "Product Information. Pylera (bismuth subcitrate potassium/metronidazo/TCN)." H2-Pharma LLC
  4. Spenard J, Aumais C, Massicotte J, et al. (2005) "Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication." Br J Clin Pharmacol, 60, p. 374-7

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.